in HLA Class I and Class II Molecules Cells Presenting MAGE-A3 Simultaneously Messenger RNA-Electroporated Dendritic

Pierre van der Bruggen and Kris ThielemansMichiels, Karine Breckpot, Francis Brasseur, Yi Zhang, Aude Bonehill, Carlo Heirman, Sandra Tuyaerts, Annelieshttp://www.jimmunol.org/content/172/11/6649J Immunol€2004; 172:6649-6657; ;Referenceshttp://www.jimmunol.org/content/172/11/6649.full#ref-list-1This article cites 68 articles, 37 of which you can access for free at: Subscriptionshttp://jimmunol.org/subscriptionsInformation about subscribing to The Journal of Immunology is online at: Permissionshttp://www.aai.org/ji/copyright.htmlSubmit copyright permission requests at: Email Alertshttp://jimmunol.org/cgi/alerts/etocReceive free email-alerts when new articles cite this article. Sign up at:

[1]  V. Brusic,et al.  Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Hao Shen,et al.  Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory , 2003, Science.

[3]  M. Cotten,et al.  MHC class II presentation of endogenously expressed antigens by transfected dendritic cells , 2001, Gene Therapy.

[4]  G. Schuler,et al.  Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells , 2002, The Journal of experimental medicine.

[5]  J. Neefjes,et al.  Recycling MHC class I molecules and endosomal peptide loading. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  B. Rocha,et al.  A Role for CD40 Expression on CD8+ T Cells in the Generation of CD8+ T Cell Memory , 2002, Science.

[7]  N. Shastri,et al.  Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Laurence Zitvogel,et al.  Antigen presentation and T cell stimulation by dendritic cells. , 2002, Annual review of immunology.

[9]  E. Gilboa,et al.  Human Dendritic Cells Transfected with RNA Encoding Prostate-Specific Antigen Stimulate Prostate-Specific CTL Responses In Vitro1 , 2000, The Journal of Immunology.

[10]  P. Romero,et al.  Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes , 1994, The Journal of experimental medicine.

[11]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[12]  Scott R. Burrows,et al.  Targeting a Polyepitope Protein Incorporating Multiple Class II-Restricted Viral Epitopes to the Secretory/Endocytic Pathway Facilitates Immune Recognition by CD4+ Cytotoxic T Lymphocytes: a Novel Approach to Vaccine Design , 1998, Journal of Virology.

[13]  F. Guarnieri,et al.  The motif Tyr-X-X-hydrophobic residue mediates lysosomal membrane targeting of lysosome-associated membrane protein 1. , 1993, The Journal of biological chemistry.

[14]  Kris Thielemans,et al.  Generation of large numbers of dendritic cells in a closed system using Cell Factories. , 2002, Journal of immunological methods.

[15]  M. Dullaers,et al.  Efficient genetic modification of murine dendritic cells by electroporation with mRNA , 2002, Cancer Gene Therapy.

[16]  Polly Matzinger,et al.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.

[17]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[18]  E. Gilboa,et al.  Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. , 2002, The Journal of clinical investigation.

[19]  S. Riddell,et al.  Targeting Antigen in Mature Dendritic Cells for Simultaneous Stimulation of CD4+ and CD8+ T Cells1 , 2001, The Journal of Immunology.

[20]  C Caux,et al.  Immunobiology of dendritic cells. , 2000, Annual review of immunology.

[21]  R. Siliciano,et al.  Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells. , 1995, Journal of immunology.

[22]  M. Brown,et al.  NPXY, a sequence often found in cytoplasmic tails, is required for coated pit-mediated internalization of the low density lipoprotein receptor. , 1990, The Journal of biological chemistry.

[23]  T. Blankenstein,et al.  CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. , 2000, Immunity.

[24]  B. Robinson,et al.  Tumor-Specific CD4+ T Cells Have a Major “Post-Licensing” Role in CTL Mediated Anti-Tumor Immunity1 , 2000, The Journal of Immunology.

[25]  Urs Christen,et al.  CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes , 2003, Nature.

[26]  M. Dullaers,et al.  Lentivirally transduced dendritic cells as a tool for cancer immunotherapy , 2003, The journal of gene medicine.

[27]  R. Steinman,et al.  Active immunization against cancer with dendritic cells: The near future , 2001, International journal of cancer.

[28]  S. Saebøe-Larssen,et al.  mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). , 2002, Journal of immunological methods.

[29]  D. Jäger,et al.  Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma , 2000, The Journal of experimental medicine.

[30]  Steven A. Rosenberg,et al.  Identification of a MHC Class II-Restricted Human gp100 Epitope Using DR4-IE Transgenic Mice , 2000, The Journal of Immunology.

[31]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[32]  D. Mitchell,et al.  RNA-transfected dendritic cells in cancer immunotherapy. , 2000, The Journal of clinical investigation.

[33]  J. Banchereau,et al.  A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment. , 1998, Immunity.

[34]  D. Pardoll,et al.  The role of CD4+ T cell responses in antitumor immunity. , 1998, Current opinion in immunology.

[35]  C. van Broeckhoven,et al.  Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. , 2001, Blood.

[36]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[37]  J. Yewdell,et al.  Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? , 1996, Journal of immunology.

[38]  E. Gilboa,et al.  Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. , 2002, Cancer research.

[39]  E. Gilboa,et al.  Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA , 1998, Nature Biotechnology.

[40]  P. Roche,et al.  Trafficking of MHC class II molecules in the late secretory pathway. , 2002, Current Opinion in Immunology.

[41]  V. Brusic,et al.  Melan-A/MART-151–73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells , 2000 .

[42]  C. Davis,et al.  Sorting signals in the MHC class II invariant chain cytoplasmic tail and transmembrane region determine trafficking to an endocytic processing compartment , 1994, The Journal of cell biology.

[43]  E. Engleman,et al.  Dendritic cells in cancer immunotherapy. , 2000, Annual review of immunology.

[44]  A. Eggermont,et al.  A MAGE-3 Peptide Presented by HLA-DR1 to CD4+ T Cells That Were Isolated from a Melanoma Patient Vaccinated with a MAGE-3 Protein1 , 2003, The Journal of Immunology.

[45]  Matteo Bellone,et al.  Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11 , 1999, The Journal of experimental medicine.

[46]  P. Bruggen,et al.  A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. , 2000, Cancer research.

[47]  Richard A. Flavell,et al.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling , 1998, Nature.

[48]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[49]  S. Nair,et al.  RNA transfected dendritic cells as cancer vaccines. , 2000, Current opinion in molecular therapeutics.

[50]  Thomas Halder,et al.  Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells , 1998, Cancer Immunology, Immunotherapy.

[51]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[52]  K. Mostov,et al.  Deletions in the cytoplasmic domain of the polymeric immunoglobulin receptor differentially affect endocytotic rate and postendocytotic traffic. , 1990, The Journal of biological chemistry.

[53]  C. Melief,et al.  Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors , 1998, The Journal of experimental medicine.

[54]  T. Boon,et al.  A MAGE‐1 peptide recognized on HLA‐DR15 by CD4+ T cells , 2001, European journal of immunology.

[55]  H. Geuze.  The role of endosomes and lysosomes in MHC class II functioning. , 1998, Immunology today.

[56]  J. Yewdell,et al.  Making sense of mass destruction: quantitating MHC class I antigen presentation , 2003, Nature Reviews Immunology.

[57]  C. Heirman,et al.  Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide. , 2003, Cancer research.

[58]  E. Gilboa,et al.  Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo , 1996, The Journal of experimental medicine.

[59]  M. Bevan,et al.  Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help , 2003, Science.

[60]  A. Eggermont,et al.  Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes , 1999, The Journal of experimental medicine.

[61]  P. Coulie,et al.  Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 , 1999, International journal of cancer.

[62]  C. Melief,et al.  Antigen Loading of MHC Class I Molecules in the Endocytic Tract , 2001, Traffic.

[63]  Kathleen R. Cho,et al.  Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[64]  M. Fukuda,et al.  Accumulation of membrane glycoproteins in lysosomes requires a tyrosine residue at a particular position in the cytoplasmic tail , 1990, The Journal of cell biology.

[65]  C. Heirman,et al.  Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells , 2003, Cancer Gene Therapy.

[66]  Charles M. Rice,et al.  HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help , 2003, Science.

[67]  J. Pieters,et al.  The MHC class II-associated invariant chain contains two endosomal targeting signals within its cytoplasmic tail. , 1993, Journal of cell science.

[68]  A Sette,et al.  Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes , 1996, The Journal of experimental medicine.